TrialAnnals of medicine2023

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.

Jia Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.